SABS Stock Summary and Trading Ideas (Sab Biotherapeutics | NASDAQ:SABS)

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Sab Biotherapeutics trades on the NASDAQ stock market under the symbol SABS.

As of May 1, 2026, SABS stock price declined to $3.47 with 624,961 million shares trading.

SABS has a beta of 0.28, meaning it tends to be less sensitive to market movements. SABS has a correlation of 0.00 to the broad based SPY ETF.

SABS has a market cap of $243.86 million. This is considered a Small Cap stock.

Last quarter Sab Biotherapeutics reported $0 in Revenue and -$.46 earnings per share. This fell short of revenue expectation by $-249,998 and missed earnings estimates by -$.13.

In the last 3 years, SABS traded as high as $11.90 and as low as $1.00.

The top ETF exchange traded funds that SABS belongs to (by Net Assets): VTI, VXF, AVSC.

SABS has outperformed the market in the last year with a return of +104.1%, while the SPY ETF gained +30.4%. However, in the most recent history, SABS shares have underperformed the stock market with its stock returning -21.0% in the last 3 month period and -9.9% for the last 2 week period, while SPY has returned +4.4% and +1.5%, respectively.

SABS support price is $3.61 and resistance is $3.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SABS shares will trade within this expected range on the day.